



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

7 November 2025
EMA/CVMP/347145/2025
Committee for Veterinary Medicinal Products

Summary of opinion¹ (initial authorisation)

Ecovaxxin MS

Common name: *Mycoplasma synoviae* vaccine (live)

On 6 November 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion², recommending the granting of a marketing authorisation for the veterinary medicinal product Ecovaxxin MS, eye drops suspension, intended for chickens. The applicant for this veterinary medicinal product is Eco Animal Health Europe Limited.

Ecovaxxin MS is an immunological medicinal product containing *Mycoplasma synoviae*, strain K5885A, live as the active substance. The benefit of Ecovaxxin MS is the active immunisation of future layer and future breeder chickens from 4 weeks of age to reduce air sac lesions, foot pad lesions (synovitis), ovarian regression and egg production losses caused by *Mycoplasma synoviae* infections.

The onset of immunity is 4 weeks after vaccination and the duration of immunity is 17 weeks after vaccination.

Ecovaxxin MS is generally well tolerated at the recommended dose.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Ecovaxxin MS and therefore recommends the granting of the marketing authorisation.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

